EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational discovery of natural medicines targeting adenosine receptors for metabolic diseases

Peng Wang, Zhiyu Xu, Yuqing Deng, Huiping Yuan, Yale Wu, Jing Jiang, Zhaohui Lyu, Zejun Li

Frontiers in Pharmacology · 02.09.2025 · 16

DOI: 10.3389/fphar.2025.1671415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.09.2025. Verfasst von Peng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Electronic Information, Hunan First Normal University, Changsha, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic diseases—including type 2 diabetes, obesity, non-alcoholic fatty liver disease, and certain cancers—pose major global public health challenges. These conditions share common mechanisms such as insulin resistance, chronic inflammation, and oxidative stress. Although medical advances have improved disease management, current treatments remain suboptimal. Natural medicines have gained increasing interest due to their safety, bioactivity, and diverse mechanisms. This study targets adenosine receptors (ARs), key regulators in glucose metabolism, lipid homeostasis, and cellular stress. As members of the G protein-coupled receptor (GPCR) family, ARs include four subtypes—A1, A2A, A2B, and A3—each with distinct pharmacological profiles. We developed a multimodal computational strategy to design natural drug candidates that simultaneously target A1 and A2A, using A2A-selective ligands as controls to explore subtype selectivity. To mitigate toxicity, we incorporated a filtering criterion for low hERG channel affinity. A random forest-based QSAR model was constructed using SMILES representations to predict compound activity. A stacked LSTM neural network was applied to generate plant-derived molecules, while reinforcement learning and Pareto optimization enabled multi-objective refinement. Evolutionary operations—crossover, mutation, and selection—were further introduced to enhance molecular diversity and performance. The proposed framework successfully generated compounds with high target selectivity, low toxicity, and it has good drug-likeness and synthetic accessibility. This work presents a robust and intelligent strategy for natural drug discovery in metabolic diseases and underscores the promising synergy between botanical medicine and artificial intelligence in therapeutic innovation.

Schlagwörter

Stichwörter der Autor:innen

adenosine receptorsartificial intelligencecomputational strategymetabolic diseasesnatural medicines

Autor:innen und Institutionen

  • School of Electronic Information, Hunan First Normal University, Changsha, China.
  • College of Computer Science and Electronic Engineering, Hunan University, Changsha, China.
  • Wenzhou University of Technology, Wenzhou, China.
  • School of Computer Science, Hunan Institute of Technology, Hengyang, China.

Zitieren

APA

Wang, P., Xu, Z., Deng, Y., Yuan, H., Wu, Y., Jiang, J., Lyu, Z., & Li, Z. (2025). Computational discovery of natural medicines targeting adenosine receptors for metabolic diseases. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1671415

Vancouver

Wang P, Xu Z, Deng Y, Yuan H, Wu Y, Jiang J, et al. Computational discovery of natural medicines targeting adenosine receptors for metabolic diseases. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1671415

BibTeX
@article{Wang2025,
  author = {Wang, Peng and Xu, Zhiyu and Deng, Yuqing and Yuan, Huiping and Wu, Yale and Jiang, Jing and Lyu, Zhaohui and Li, Zejun},
  title = {Computational discovery of natural medicines targeting adenosine receptors for metabolic diseases},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1671415}
}
Kostenlos starten →